NCT02253316View on ClinicalTrials.gov

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

236

Participants

Timeline

Start Date

January 20, 2015

Primary Completion Date

February 5, 2020

Study Completion Date

August 31, 2026

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

Ixazomib

DRUG

Lenalidomide

DRUG

Dexamethasone

Trial Locations (10)

10029

Icahn School of Medicine at Mount Sinai, New York

30322

Emory University - Winship Cancer Institute, Atlanta

37203

Tennessee Oncology, PLLC, Nashville

43210

Ohio State University Comprehensive Cancer Center, Columbus

48201

Karmanos Cancer Institute, Detroit

55905

Mayo Clinic, Rochester

62864

Washington University School of Medicine, St Louis

80218

Colorado Blood Cancer Institute, Denver

91010

City of Hope, Duarte

94143

University of California, San Francisco, San Francisco

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

collaborator

Multiple Myeloma Research Consortium

NETWORK

lead

Washington University School of Medicine

OTHER

NCT02253316 - Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma | Biotech Hunter | Biotech Hunter